Back to discover
Disease

Ischemia

Late-stage therapeutic developmentEmerging researchSteady momentum
MeSHIschemia
4
Publications
23
Clinical trials
1
Related conditions
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets.

Research2024-01-08Signal transduction and targeted therapy

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.

Research2023-04-25Lancet (London, England)

An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.

Research2020-10-01European heart journal

Global vascular guidelines on the management of chronic limb-threatening ischemia.

Research2019-05-28Journal of vascular surgery

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones5View
Results expected 3
Recently completed 1
Other updates 1
Activity timeline5

Clinical trials

17 sponsors · 0 new · 1 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
23
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the Incidence of Ischemia-Driven Major Amputation, Clinically Driven Target Lesion Revascularization, and Clinically Relevant Target Lesion Occlusion After Revascularization of Lesions Below the Knee in Patients With Symptomatic Rutherford 3-5 Peripheral Artery Disease

Phase 3 · Recruiting · Mercator MedSystems, Inc.

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)

Phase 3 · Recruiting · Fondation Ophtalmologique Adolphe de Rothschild

Multicenter Randomized Prospective Controlled Trial of the Clinical Effectiveness of a Best Endovascular Treatment Versus a Best Endovascular Treatment in Combination With Gene Therapy for Severe Limb Ischemia

Phase 4 · Recruiting · Amur State Medical Academy

An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

Phase 4 · Recruiting · Cell Biopeutics Resources Sdn Bhd

An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.

Phase 4 · Recruiting · Cell Biopeutics Resources Sdn Bhd

ORal Antibiotics in Acute Mesenteric Ischemia: a Multicenter Randomized Controlled Trial

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris
Recruiting

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the Incidence of Ischemia-Driven Major Amputation, Clinically Driven Target Lesion Revascularization, and Clinically Relevant Target Lesion Occlusion After Revascularization of Lesions Below the Knee in Patients With Symptomatic Rutherford 3-5 Peripheral Artery Disease

Phase 3 · Recruiting · Mercator MedSystems, Inc.

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)

Phase 3 · Recruiting · Fondation Ophtalmologique Adolphe de Rothschild

Multicenter Randomized Prospective Controlled Trial of the Clinical Effectiveness of a Best Endovascular Treatment Versus a Best Endovascular Treatment in Combination With Gene Therapy for Severe Limb Ischemia

Phase 4 · Recruiting · Amur State Medical Academy

An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

Phase 4 · Recruiting · Cell Biopeutics Resources Sdn Bhd

An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.

Phase 4 · Recruiting · Cell Biopeutics Resources Sdn Bhd

ORal Antibiotics in Acute Mesenteric Ischemia: a Multicenter Randomized Controlled Trial

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris
Recently completed

Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus Histidine, Tryptophan and Ketoglutarate Solution Cardioplegia Solution in Cardiac Surgery

Phase 3 · Completed · Assiut University

Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging

Phase 4 · Completed · M.D. Anderson Cancer Center

Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion : a Randomized, Double-blind Clinical Trial

Phase 4 · Completed · Affiliated Hospital of Nantong University

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous NA-1 Initiated by Paramedics in the Field for Acute Cerebral Ischemia Within Three Hours of Symptom Onset

Phase 3 · Completed · NoNO Inc.

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase III Clinical Study to Assess Efficacy of PMZ-1620 Along With Standard Treatment in Patients of Acute Ischemic Stroke

Phase 3 · Completed · Pharmazz, Inc.

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Phase 3 · Completed · Pluristem Ltd.

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20192024
Most influential

Global vascular guidelines on the management of chronic limb-threatening ischemia.

Journal of vascular surgery · 2019 · 981 cites

An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.

European heart journal · 2020 · 561 cites

Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets.

Signal transduction and targeted therapy · 2024 · 390 cites

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.

Lancet (London, England) · 2023 · 256 cites
Recent publications

Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets.

Signal transduction and targeted therapy · 2024 · 390 cites

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.

Lancet (London, England) · 2023 · 256 cites

An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.

European heart journal · 2020 · 561 cites

Global vascular guidelines on the management of chronic limb-threatening ischemia.

Journal of vascular surgery · 2019 · 981 cites
Major themes6
  • Angioplasty, Balloon, Coronary1
  • Cardiology1
  • Coronary Vessels1
  • Ocimum basilicum1
  • Peripheral Arterial Disease1
  • Reperfusion Injury1
Leading journals4
  • European heart journal1
  • Journal of vascular surgery1
  • Lancet (London, England)1
  • Signal transduction and targeted therapy1
Leading researchers8
  • Bradbury AW2
  • Abbott JD1
  • Al-Lamee R1
  • Appelman Y1
  • Badimon L1
  • Bate GR1
  • Baumbach A1
  • Berry C1
Affiliations (unnormalised)6
  • A.O.U. 'Policlinico-Vittorio Emanuele'1
  • Advocate Lutheran General Hospital1
  • Bart's Heart Centre1
  • Basic medical school1
  • Baylor College of Medicine1
  • Birmingham Clinical Trials Unit1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Peripheral Arterial Disease2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.

Identifiers
MeSHIschemia
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.